Clinical Trials Logo

Bladder Cancer clinical trials

View clinical trials related to Bladder Cancer.

Filter by:

NCT ID: NCT00744744 Completed - Bladder Cancer Clinical Trials

Health-Related Quality of Life in Patients With Bladder Cancer

Start date: May 2008
Phase: N/A
Study type: Observational

RATIONALE: Gathering information about quality of life in patients with cancer may improve the ability to plan treatment and may help patients live more comfortably. PURPOSE: This clinical trial is studying health-related quality of life in patients with bladder cancer.

NCT ID: NCT00729287 Recruiting - Bladder Cancer Clinical Trials

Selenium in Preventing Cancer Recurrence in Patients With Bladder Cancer

Start date: June 2008
Phase: Phase 3
Study type: Interventional

RATIONALE: Chemoprevention is the use of certain drugs to keep cancer from forming, growing, or coming back. The use of selenium may keep bladder cancer from growing or coming back. It is not yet known whether selenium is more effective than a placebo in preventing cancer recurrence in patients with bladder cancer. PURPOSE: This randomized phase III trial is studying selenium to see how well it works compared with a placebo in preventing cancer recurrence in patients with bladder cancer.

NCT ID: NCT00722553 Completed - Bladder Cancer Clinical Trials

Study of Pralatrexate to Treat Advanced or Metastatic Relapsed Transitional Cell Carcinoma of the Urinary Bladder

Start date: July 2008
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine whether pralatrexate, given with vitamin B12 and folic acid, is effective in the treatment of advanced or metastatic bladder cancer. The study will also investigate the safety of pralatrexate with vitamin B12 and folic acid in this patient population. Additionally, this study includes the collection of blood samples to investigate the pharmacokinetics (PK) of pralatrexate in this patient population (PK is the activity of a drug in the body over a period of time, including how the drug is absorbed, distributed in the body, localized in the tissues, and excreted from the body).

NCT ID: NCT00714948 Terminated - Bladder Cancer Clinical Trials

Gemcitabine and Split-dose Cisplatin (GC) Plus Sorafenib in Chemotherapy-naïve Patients With Locally Advanced or Metastatic Urothelial Carcinoma

Start date: July 2008
Phase: Phase 2
Study type: Interventional

Standard chemotherapy drugs generally work by killing rapidly dividing cells in your body. Cancers cells are some of the most rapidly dividing cells and that is why chemotherapy can be effective in some patients. Gemcitabine and Cisplatin are an effective and standard drug combination used to treat locally advanced and metastatic urothelial cancer. However, these drugs do not shrink tumors in all patients and when they do, it is generally for a limited amount of time. This has led scientists to look for different ways to treat cancer. New drugs have been developed to treat cancer that work differently than standard chemotherapy drugs. These drugs attempt to decrease the blood supply to tumors. By doing so, this may limit the tumor's source of oxygen and nutrients and prevent the tumor from growing. Sorafenib is an example of a drug that works in this way. In some patients with advanced kidney cancer, sorafenib alone has been shown to slow the progression of their disease. The purpose of this study is to find out what effects, good and/or bad, the combination of gemcitabine, cisplatin, and sorafenib has on you and your cancer.

NCT ID: NCT00709462 Completed - Breast Cancer Clinical Trials

A Study of CDX-1307, in Patients With Incurable Breast, Colorectal, Pancreatic, Ovarian or Bladder Cancer (CDX 1307-01)

Start date: March 2004
Phase: Phase 1
Study type: Interventional

This research study is for individuals who have advanced breast, colon, pancreatic, ovarian or bladder cancer. Celldex Therapeutics, Inc. is testing a form of immune therapy (vaccine) to see if it can be used to make the immune system attack the cancer. The study includes administration of additional treatments, in combination, thought to enhance the immune response effect. (CDX 1307-01)

NCT ID: NCT00696579 Completed - Bladder Cancer Clinical Trials

Bacillus of Calmette and Guerin (BCG) Versus Gemcitabine For Intravesical Therapy In High Risk Superficial Bladder Cancer

Start date: January 2004
Phase: Phase 1/Phase 2
Study type: Interventional

A significant number of patients with high risk superficial bladder cancer has progression to invasive disease. No consensus exists regarding the optimal treatment to decrease the recurrence and progression rate. The aim of this research is to evaluate the safety, tolerability and efficacy of adjuvant intravesical gemcitabine vs. BCG in the treatment of high-risk superficial bladder cancer

NCT ID: NCT00694915 Completed - Bladder Cancer Clinical Trials

Study of Mycobacterium w in Superficial Transitional Cell Carcinoma of Bladder

STCC
Start date: August 28, 2008
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine and compare the effect of this treatment on recurrence rate and to assess the toxicity in both arms of patients with STCC. Other objectives include determining the effects of this treatment on quality of life, and comparing the effect of Mycobacterium w on time to tumor progression.

NCT ID: NCT00694798 Completed - Bladder Cancer Clinical Trials

Study of Mycobacterium w in BCG Refractory Superficial Transitional Cell Carcinoma of Bladder

STCC
Start date: October 2008
Phase: Phase 1
Study type: Interventional

The primary purpose of this study is to evaluate the response rate of this treatment (Mw) in patients with BCG refractory superficial transitional cell carcinoma. Other objectives include detecting the effect of Mw on Time to Tumor progression and evaluating safety.

NCT ID: NCT00666978 Completed - Lung Cancer Clinical Trials

Health Education Counseling With or Without Bupropion in Helping African Americans Stop Smoking

Start date: December 2007
Phase: Phase 4
Study type: Interventional

RATIONALE: A stop-smoking plan that includes health education counseling and bupropion may help African-American smokers stop smoking. It is not yet known whether health education counseling is more effective with or without bupropion in helping African Americans stop smoking. PURPOSE: This clinical trial is studying health education counseling and bupropion to see how well they work compared with a placebo and health education counseling in helping African Americans smokers stop smoking.

NCT ID: NCT00661609 Completed - Bladder Cancer Clinical Trials

A Phase II Study of AZD4877 (a Novel Anti-mitotic Agent) in Advanced Bladder Cancer

Start date: May 2008
Phase: Phase 2
Study type: Interventional

The purpose of this Phase II study is to determine if AZD4877, an experimental drug that is a novel anti-mitotic agent (Eg5 or Kinesin Spindle Protein inhibitor that interferes with tumor cell division leading to tumor growth), can reduce tumor sizes in patients with bladder cancer